Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma
Alberto Sandri,Francesco Guerrera,Matteo Roffinella,Stefania Olivetti,Lorena Costardi,Alberto Oliaro,Pier Luigi Filosso,Paolo Olivo Lausi,Enrico Ruffini +8 more
TL;DR: The EORTC prognostic index proved to be an independent prognostic factor in a cohort of patients and therefore is a reliable and valid instrument that may be implemented in the daily practice.
read more
Abstract: Background: To assess the trend of our surgical patients affected by malignant pleural mesothelioma (MPM) and submitted to diagnostic/palliative or curative surgical procedures and to validate the European Organisation for Research and Treatment of Cancer (EORTC) prognostic score in our patient population.
Methods: This is a cohort study of patients submitted to surgery for MPM from January 2007 to December 2013. Primary outcome was overall survival (OS). Univariate and multivariate-adjusted comparisons by EORTC prognostic score for OS were accomplished using Cox method. Adjusted models included the following clinical variables: kind of procedure, smoking habit, asbestos exposure, Charlson’s Comorbidity Index (CCI), clinical tumor stage, adjuvant chemotherapy, dyspnoea, chest pain and haematological variables according to the score features. Nomenclature of the surgical procedures matches the International Association for the Study Lung Cancer (IASLC)/International Mesothelioma Interest Group (iMIG).
Results: One-hundred sixty-six consecutive cases were collected: the median age at surgery was 73 years and 123 patients (75%) had a history of asbestos exposure. Ninty patients (54%) were submitted to a palliative/diagnostic thoracoscopy, 30 to pleurectomy/decortication (P/D), and 6 to extra-pleural pneumonectomy (EPP). Clinical TNM stages were as follows: 99 (60%) stage I–II, 34 (20%) stage III and 33 (20%) stage IV. The median follow-up (FU) was 19 months [interquartile range (IQR), 9–31 months] and the FU-completeness was 98%. By the end of the study 130 patients died (78%). One- and 3-year OS was 60% and 36%, respectively. Patients submitted to EPP and P/D showed a better survival (P=0.013). Multivariable model showed an independent prognostic value of EORTC score (HR =2.86, P Conclusions: In selected patients, aggressive surgical approaches, although not radical, may still be beneficial. The EORTC prognostic index proved to be an independent prognostic factor in our cohort of patients and therefore is a reliable and valid instrument that may be implemented in the daily practice.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
ERS/EACTS statement on the management of malignant pleural effusions.
Anna C. Bibby,Anna C. Bibby,Patrick Dorn,Ioannis Psallidas,José M. Porcel,Julius Janssen,Marios Froudarakis,Dragan Subotic,P Astoul,Peter B. Licht,Ralph A. Schmid,Arnaud Scherpereel,Najib M. Rahman,Giuseppe Cardillo,Nick A Maskell,Nick A Maskell +15 more
TL;DR: The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE and the LENT score was identified as a validated tool for predicting survival in MPE, with Brims' prognostic score demonstrating utility in mesothelioma prognostication.
Surgery in Malignant Pleural Mesothelioma.
TL;DR: The role of surgical resection is summarized, specifically macroscopic complete resection, performed as extrapleural pneumonectomy or extended pleurectomy/decortication in multimodality treatment settings and advocate for optimal patient selection for one or the other procedure.
72
Malignant pleural mesothelioma: recent developments.
TL;DR: Overall, there has not been a real breakthrough in the treatment of MPM, and targeted therapies, immunotherapy, and vaccination are considered as new promising strategies.
42
Surgery for malignant pleural mesothelioma
Michael A. Archer,Raphael Bueno +1 more
TL;DR: The frontiers of mesothelioma research and treatment include an urgent search for biomarkers that can reliably detect early stage cancer in at-risk populations, clinical tests or indices thatCan reliably predict prognosis among surgical candidates and the development of efficacious drugs and targete...
33
Clinical staging of malignant pleural mesothelioma: current perspectives.
Maria Bonomi,Costantino De Filippis,Egesta Lopci,Letizia Gianoncelli,Giovanna Rizzardi,Eleonora Cerchiaro,Luigi Bortolotti,Alessandro Zanello,Giovanni Luca Ceresoli +8 more
- 18 Aug 2017
TL;DR: Molecular reclassification of MPM and gene expression or miRNA prognostic models have the potential to improve prognostication and patient selection for a proper treatment algorithm; however, they await prospective validation to be introduced in clinical practice.
References
Prognostic factors in patients with pleural mesothelioma : The European Organization for Research and Treatment of Cancer Experience
Desmond Curran,Tarek Sahmoud,Patrick Therasse,J. Van Meerbeeck,Pieter E. Postmus,G. Giaccone +5 more
TL;DR: Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data may help to design new clinical trials in pleural Mesot Helioma by selecting more homogenous groups of patients.
541
Prognostic factors for malignant mesothelioma in 142 patients : validation of CALGB and EORTC prognostic scoring systems
John G. Edwards,Keith R. Abrams,J N Leverment,T.J. Spyt,David A. Waller,Kenneth J. O'Byrne +5 more
- 01 Jan 2000
TL;DR: In this paper, the authors evaluated the prognostic variables, validated the EORTC and CALGB prognostic groups, and evaluated survival in a series of 142 patients presenting in Leicester since 1988.
294
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
Loic Lang-Lazdunski,Andrea Bille,Rohit Lal,Paul Cane,Emma McLean,David Landau,Jeremy P.C. Steele,James Spicer +7 more
TL;DR: P/D, hyperthermic pleural lavage with povidone-iodine, and adjuvant chemotherapy were superior to neoadjuvant chemotherapy, EPP, andadjuvant radiotherapy in patients with malignant pleural mesothelioma.
171
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
Ottavio Rena,Caterina Casadio +1 more
TL;DR: MPM patients submitted to EPP had a higher post-operative complication rate, a worse long-term QoL, a shorter residual life time after recurrent disease, despite a similar long- term survival when compared to P/D, and MPM patients returned at baseline levels after 12 months after treatment completion.
107
Prognostic factors for mesothelioma.
TL;DR: Molecular data will provide prognostication of exceptional accuracy, biologic insights, and targets for improved treatment in malignant mesothelioma.
69